Evidence map›Paper›PMID 35198081›Full record

ArticleTheranostics2022

Unlabeled aspirin as an activatable theranostic MRI agent for breast cancer.

KowsalyaDevi Pavuluri, Ethan Yang, Vinay Ayyappan, Kanchan Sonkar, Zheqiong Tan, Caitlin M Tressler, Shaowei Bo, Adnan Bibic, Kristine Glunde, Michael T McMahon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

KowsalyaDevi PavuluriDivision of MR Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Ethan YangDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Vinay AyyappanDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Kanchan SonkarDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Zheqiong TanDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Caitlin M TresslerDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Shaowei BoDivision of MR Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Adnan BibicF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD.
Kristine GlundeDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Michael T McMahonDivision of MR Research, The Russell H. Morgan Department of Radiology and Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, MD.
Kennedy Krieger Institute · USHuazhong University of Science and Technology · CNJohns Hopkins University · US

Funding

Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
Hypoxia-derived molecular MSI signatures to predict breast cancer outcomeR01CA213492 · NCI · JOHNS HOPKINS UNIVERSITY · PI GLUNDE, KRISTINE, HEEREN, RON · 2017 to 2021
$2.1M
Molecular studies of the MR-detectable oncometabolite glycerophosphocholineR01CA213428 · NCI · JOHNS HOPKINS UNIVERSITY · PI GLUNDE, KRISTINE · 2017 to 2021
$1.9M
Reprogramming of creatine metabolism in breast cancer metastasisR01CA264901 · NCI · JOHNS HOPKINS UNIVERSITY · PI Kristine Glunde · 2022 to 2026
$1.8M
NCI NIH HHS R01 CA213428NCI NIH HHS R01 CA213492NCI NIH HHS R01 CA264901NIBIB NIH HHS P41 EB024495
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsAnimalsAspirinContrast MediaDinoprostoneFemaleHumansMagnetic Resonance ImagingMiceTheranostic NanomedicineAspirinContrast MediaDinoprostoneaspirinbreast cancerCESTgadoliniumMRIsalicylic acid

Identifiers

PMID35198081
PMCPMC8825591
OpenAlexW4210624962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.